Linnaeus Therapeutics Inc., of Haddonfield, N.J., said it closed a $12 million series B financing led by Kairos Ventures with participation by the Penn Medicine Co-Investment Fund at the University of Pennsylvania. The company intends to use the proceeds to conduct its phase I/II trial of its lead compound, LNS-8801, in patients with advanced cancer.